CCN1

Across TCGA pan-cancer cohorts, CCN1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CCN1 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CCN1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCN1 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where CCN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.287	0.492	<.001	77	view →
CCRCC	DFS	Quartile	All	0.364	0.979	.001	38	view →
LUAD	OS	Median	III,IV	0.308	1.000	.001	22	view →
HNSC	DFS	Median	All	0.291	1.000	.001	16	view →
LSCC	DFS	Quartile	II,III,IV	0.921	0.215	.024	3	view →
GBM	DFS	Median	All	0.211	0.313	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CCN1–PDAC (DFS)

Open the PDAC breakdown →